Recombinant
RabMAb

Anti-CD31 antibody [EPR17260-265] (ab182982)

Overview

  • Product name
    Anti-CD31 antibody [EPR17260-265]
    See all CD31 primary antibodies
  • Description
    Rabbit monoclonal [EPR17260-265] to CD31
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    Recombinant fragment within Mouse CD31 aa 400-600. The exact sequence is proprietary.
    Database link: Q08481

  • Positive control
    • WB: His-tagged mouse CD31 recombinant protein (aa18-590); bEnd.3 cell lysate; mouse platelet and lung lysate. IP: bEnd.3 whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Applications

Our Abpromise guarantee covers the use of ab182982 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 110-130 kDa (predicted molecular weight: 81 kDa).
IP 1/40.

Target

  • Function
    Induces susceptibility to atherosclerosis (By similarity). Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) under most inflammatory conditions. Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes. Prevents phagocyte ingestion of closely apposed viable cells by transmitting 'detachment' signals, and changes function on apoptosis, promoting tethering of dying cells to phagocytes (the encounter of a viable cell with a phagocyte via the homophilic interaction of PECAM1 on both cell surfaces leads to the viable cell's active repulsion from the phagocyte. During apoptosis, the inside-out signaling of PECAM1 is somehow disabled so that the apoptotic cell does not actively reject the phagocyte anymore. The lack of this repulsion signal together with the interaction of the eat-me signals and their respective receptors causes the attachment of the apoptotic cell to the phagocyte, thus triggering the process of engulfment). Isoform Delta15 is unable to protect against apoptosis. Modulates BDKRB2 activation. Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in human umbilical cord vein cells (HUVEC).
  • Tissue specificity
    Expressed on platelets and leukocytes and is primarily concentrated at the borders between endothelial cells. Isoform Long predominates in all tissues examined. Isoform Delta12 is detected only in trachea. Isoform Delta14-15 is only detected in lung. Isoform Delta14 is detected in all tissues examined with the strongest expression in heart. Isoform Delta15 is expressed in brain, testis, ovary, cell surface of platelets, human umbilical vein endothelial cells (HUVECs), Jurkat T-cell leukemia, human erythroleukemia (HEL) and U937 histiocytic lymphoma cell lines (at protein level).
  • Sequence similarities
    Contains 6 Ig-like C2-type (immunoglobulin-like) domains.
  • Domain
    The Ig-like C2-type domains 2 and 3 contribute to formation of the complex with BDKRB2 and in regulation of its activity.
  • Post-translational
    modifications
    Phosphorylated on Ser and Tyr residues after cellular activation. In endothelial cells Fyn mediates mechanical-force (stretch or pull) induced tyrosine phosphorylation.
  • Cellular localization
    Membrane. Cell junction. Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells and Cell junction. Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells.
  • Information by UniProt
  • Database links
  • Alternative names
    • Adhesion molecule antibody
    • CD31 antibody
    • CD31 antigen antibody
    • CD31 EndoCAM antibody
    • EndoCAM antibody
    • FLJ34100 antibody
    • FLJ58394 antibody
    • GPIIA antibody
    • GPIIA' antibody
    • PECA1 antibody
    • PECA1_HUMAN antibody
    • Pecam 1 antibody
    • PECAM 1 CD31 EndoCAM antibody
    • PECAM antibody
    • PECAM-1 antibody
    • Pecam1 antibody
    • Platelet and endothelial cell adhesion molecule 1 antibody
    • Platelet endothelial cell adhesion molecule antibody
    • Platelet/endothelial cell adhesion molecule 1 antibody
    see all

Images

  • Lane 1 : Anti-CD31 antibody [EPR17260-265] (ab182982) at 1/20000 dilution
    Lane 2 : Anti-CD31 antibody [EPR17260-265] (ab182982) at 1/100000 dilution

    All lanes : His-tagged mouse CD31 recombinant protein (aa18-590) 10 ng

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Developed using the ECL technique.

    Predicted band size: 81 kDa
    Observed band size: 100 kDa (why is the actual band size different from the predicted?)


    Exposure time: 3 minutes
  • Lanes 1-2 : Anti-CD31 antibody [EPR17260-265] (ab182982) at 1/1000 dilution
    Lane 3 : Anti-CD31 antibody [EPR17260-265] (ab182982) at 1/2000 dilution

    Lane 1 : Mouse platelet lysate
    Lane 2 : Mouse lung lysate
    Lane 3 : bEnd.3 (mouse brain endothelioma), whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Developed using the ECL technique.

    Predicted band size: 81 kDa
    Observed band size: 110-130 kDa (why is the actual band size different from the predicted?)



    Blocking: 5% NFDM /TBST.

    Exposure time:

    Lane 1: 3 minutes

    Lanes 2-3: 1 second

    The expression MW observed is consistent with what has been described in the literature (PMID: 18388311; 12433657).

  • CD31 was immunoprecipitated from 1 mg bEnd.3 (mouse brain endothelioma cell line) whole cell lysate with ab182982 at 1/40 dilution. Western blot was performed from the immunoprecipitate using ab182982 at 1/1000 dilution. VeriBlot for IP secondary antibody (HRP) (ab131366), was used as secondary antibody at 1/10000 dilution.

    Lane 1: bEnd.3 whole cell lysate  10 μg (Input).
    Lane 2: ab182982 IP in bEnd.3 whole cell lysate (+).
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab182982 in bEnd.3 whole cell lysate (-)

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 seconds.

References

ab182982 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab182982.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up